Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) have been given a consensus rating of “Moderate Buy” by the seven brokerages that are presently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company.

BIOVF has been the topic of a number of research analyst reports. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Finally, Pareto Securities downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Monday, June 29th.

Swedish Orphan Biovitrum Stock Performance

Shares of OTCMKTS:BIOVF opened at $48.13 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.55 and a debt-to-equity ratio of 0.20. The company has a 50-day moving average price of $48.38 and a 200-day moving average price of $45.79. The company has a market cap of $17.13 billion, a price-to-earnings ratio of 106.95 and a beta of 0.33. Swedish Orphan Biovitrum has a 12 month low of $29.18 and a 12 month high of $49.03.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Swedish biopharmaceutical company focused on developing, manufacturing and commercializing therapies for rare diseases. Its principal areas of activity include hematology, immunology and specialty care, with an emphasis on conditions that have limited treatment options and relatively small patient populations.

Sobi’s portfolio includes treatments for hemophilia and other bleeding disorders, such as Elocta, Alprolix and Vonvendi, as well as medicines for immune-mediated and hematologic conditions.